Fig. 3
From: circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
circCDYL2 promotes trastuzumab-resistant of HER2+ BC cells. A qRT-PCR analysis of circCDYL2 and linear CDYL2 in both BT474-R, SK-BR-3-R, P-BT474 and P-SK-BR-3 cells after circCDYL2 silencing or over-expressing by circCDYL2 specific siRNAand over-expressing plasmid. B-D The cell viability of BC cells after treatments with circCDYL2 siRNA or over-expressing circCDYL2 plasmid or trastuzumab, as detected by CCK8 assay (B), cell viability assay (C) and colony formation (D). E circCDYL2 promotes the trastuzumab resistant of BC cells shown by the EdU assay. 2 μg/ml Trastuzumab was added to cells every day. Scale bar, 50 μm. All experiments were repeated at least 3 times. *P < 0.05, **P < 0.01, ***P < 0.005. Error bars indicate S.E.M.